ACESION PHARMA APS has a total of 16 patent applications. It increased the IP activity by 150.0%. Its first patent ever was published in 2013. It filed its patents most often in EPO (European Patent Office), WIPO (World Intellectual Property Organization) and Canada. Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are BRUNCKO MILAN, LUNDBECK LA JOLLA RESEARCH CENTER INC and STEP PHARMA S A S.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 4 | |
#2 | WIPO (World Intellectual Property Organization) | 4 | |
#3 | Canada | 3 | |
#4 | China | 3 | |
#5 | United States | 2 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Heterocyclic compounds | |
#3 | Medical preparations |
# | Name | Total Patents |
---|---|---|
#1 | Mete Antonio | 10 |
#2 | Sørensen Ulrik Svane | 7 |
#3 | Mete Anthonio | 4 |
#4 | Sorensen Ulrik Svane | 3 |
#5 | Sorensen Ulrik | 2 |
#6 | Bentzen Bo Hjorth | 2 |
#7 | Diness Jonas Goldin | 2 |
#8 | Sørensen Ulrik | 2 |
#9 | Grunnet Morten | 2 |
#10 | Stroebaek Dorte | 1 |
Publication | Filing date | Title |
---|---|---|
WO2019038315A1 | Benzimidazole derivatives useful as potassium channel inhibitors | |
CA3072648A1 | Substituted benzimidazoles as potassium channel inhibitors | |
WO2017144183A1 | Novel potassium channel inhibitors | |
EP2861254A2 | Pharmaceutical compositions for combination therapy | |
WO2013104577A1 | Benzimidazolyl-acetamide derivatives useful as potassium channel modulators |